The Food and Drug Administration has announced plans to remove the agency’s strongest black box warnings from hormone replacement therapy (HRT) products prescribed for menopausal symptoms. Black box warnings are intended to signal the most serious potential harms, but the FDA said they have contributed to fear and confusion about HRT over the past two decades.
HHS Secretary Robert F. Kennedy Jr. called the change a correction of “outdated science and bureaucratic inertia,” saying it will help return decisions to evidence-based care. FDA Commissioner Marty Makary, MD, MPH, said millions of women may have been denied HRT benefits because labels delivered an exaggerated perception of risk.
The FDA is asking manufacturers to revise labeling language that addresses risks tied to cardiovascular disease, breast cancer, and dementia. The agency is not proposing removal of warnings about endometrial cancer for systemic estrogen-only products, which will remain on those labels. The update follows a review of recent literature and an expert panel reassessment, including reanalysis of data from people who began HRT within 10 years of menopause onset.
Officials said removing the black box warnings aims to reduce HRT underuse for menopause symptom relief and to lower stigma that can prevent patients and clinicians from discussing or prescribing therapy. Experts expect the change to increase clinician awareness, prompt better education across specialties, and expand access to individualized care for people experiencing menopause.
HRT has been used for decades to treat symptoms such as hot flashes, night sweats, and sleep disruption; it was first approved for certain menopausal symptoms in 1941. Use of HRT dropped sharply after the Women’s Health Initiative (WHI) studies in the 1990s linked hormone therapy to higher risks of cardiovascular events, breast cancer, and blood clots, prompting a roughly 45% decline in prescriptions and the addition of black box labels. Some researchers have since argued that portions of the WHI findings were misinterpreted or inappropriately generalized to all menopausal patients.
Clinicians note that HRT’s symptom-relief benefits are often strongest when therapy is started within about 10 years of menopause onset, and that treatment decisions should remain individualized. Patients and providers should weigh potential benefits and risks based on age, medical history, and timing relative to menopause.
Supporters of the FDA’s labeling change say it should encourage more open, evidence-based conversations between patients and providers and increase referrals to clinicians with menopause expertise. The agency’s move does not remove all cautions: some risk language will remain on HRT products, and endometrial cancer warnings for certain estrogen-only therapies will be retained. Still, the shift is intended to provide more nuanced guidance aligned with current evidence and improve access to treatment options.
